



ALEXANDRIA, VA 22313-1450
IF UNDELIVERABLE RETURN IN TEN DAYS

OFFICIAL BUSINESS

AN EQUAL OPPORTUNITY EMPLO

004205065 JUN 29 2005
MAILED FROM ZIP CODE 22314



IMMU051 9810120101204 08 07/06/05
FORWARD TIME EXP RTN TO SEND

IMMUNEX CORP
1201 AMGEN CT W
SEATTLE WA 98119-3105

RETURN TO SENDER



UNITED STATES PATENT AND TRADEMARK OFFICE

JFW
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/664,456	09/19/2003	Douglas P. Cerretti	2517-USB	5621
7590	06/29/2005		EXAMINER	
Suzanane A. Sprunger, Ph.D. Immunex Corporation Law Department 51 University Street Seattle, WA 98101			MOORE, WILLIAM W	
			ART UNIT	PAPER NUMBER
			1656	
			DATE MAILED: 06/29/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED
OIPENAP

JUL 12 2005

Office Action Summary	Application No.	Applicant(s)
	10/664,456	CERRETTI, DOUGLAS P.
	Examiner William W. Moore	Art Unit 1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-31 is/are pending in the application.
- 4a) Of the above claim(s) 12,13,24 and 25 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-11,14-23 and 26-31 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 20030919
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: _____

DETAILED ACTION

Preliminary Amendment and Specification

Applicant's Preliminary Amendment filed with the application on 19 September 2003 has been entered, revising information at page 1, line 9, of the specification, deleting the terms "http" and associated punctuation at pages 33, 34, and 47 of the specification, and providing the new claims 1-31.

The disclosure is objected to because of the following informalities: It is noted that the amendment to page 1 of the specification does not indicate the status of the parent application serial No. 09/890,323, which is now abandoned. Applicant is invited to amend the specification to indicate the status of the parent application in response to this communication. While several instances of signals for embedded hyperlinks were altered in Applicant's Preliminary Amendment, the disclosure is objected to because it still contains embedded hyperlinks and/or other form of browser-executable code. See page 4 at lines 12-14. Applicant is required to delete all instances of embedded hyperlinks and/or other form of browser-executable code wherever they occur in the specification. See MPEP § 608.01. Appropriate correction is required.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. § 121:

1. Claims 1-11, 14-23, and 26-31, drawn to an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:12, classified in class 435, subclass 219.
2. Claims 1-10, 12, 14-22, 24, and 26-31, drawn to an isolated polypeptide that comprises the amino acid sequence of SEQ ID NO:13, classified in class 435, subclass 219.
3. Claims 1-10, 13-22, and 25-31, drawn to an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:14, classified in class 435, subclass 219.

Inventions of Groups 1, 2 and 3 are unrelated, each to the other, because each comprises a distinct product having a unique primary structure. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are not disclosed

Art Unit: 1652

to be used together and require separate searches in the patent and non-patent literature.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

During a telephone conversation with Ms. Susan Lingenfelter on 10 June 2005 a provisional election was made with traverse to prosecute the invention of Group I, comprising claims 1-11, 14-23, and 26-31, drawn to an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:12. Affirmation of this election must be made by applicant in replying to this Office action. Claims 12, 13, 24 and 25 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention. Claims 1-10, 14-22, and 26-31 are objected to because they are drawn, in part, to non-elected subject matter.

Claim Rejections - 35 USC § 101

35 U.S.C. §101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 1-11, 14-23, and 26-31 are rejected under 35 U.S.C. § 101 because the claimed invention lacks patentable utility.

A claimed invention must possess a specific, substantial and credible *in vitro* or *in vivo* utility. It is agreed that SEQ ID NO:12 encodes a metalloprotease comprising a protease domain and a disintegrin domain and that both domains share detectable degrees of amino acid sequence identity with protease and disintegrin domains in the prior art. The specification, however, discloses no specific *in vitro* or *in vivo* utility for either the disintegrin domain or the protease domain of the SVPH-1a amino acid sequence set forth in SEQ ID NO:12. The specification teaches that mRNA transcripts encoding the SVPH-1a metalloprotease can be detected in human testicular tissue and, at page 1, that disintegrin domains generically are known to bind to integrins, molecules expressed on the surface of cells, "involved in cell-to-cell adhesion, cell-to-matrix

Art Unit: 1652

adhesion, and inflammatory responses". The specification also teaches, at page 3, that disintegrin domains of proteins in snake venom "prevent[] platelet aggregation and . . . act[] as an anticoagulant", and further teaches, page 5, that that the SVPH-1a metalloprotease may be used to study "cell/cell and cell/matrix interactions involved in cellular processes . . . as well as those [processes] involved in the immune system". In addition to these teachings generic to disintegrin domains, the specification proposes utilities generic to proteins as a whole, e.g., in the final paragraph of page 38, that the SVPH-1a polypeptide may be used as a "research tool for studying the biological effects that result from inhibiting binding . . . interactions on different cell types" and, at pages 39-43 that either the protease or the disintegrin domain might be used as molecular weight markers and as controls for peptide fragmentation.

But the specification is silent about the nature of any cellular process that requires the presence or activity of the integral SVPH-1a metalloprotease or the 103-amino acid disintegrin domain required by claims 1-5, or the closely-related metalloproteases and disintegrin domains defined by the hybridization conditions or the requirement for 95% identity stated in claims 6-11, 14-23, 26 and 28-31. The specification cannot identify the nature of the activity of the protease domain, whether exoproteolytic or endoproteolytic, whether it acts within a cell or acts outside a cell, and also fails to identify the nature of any substrate for protease domain. Similarly, the specification is silent as to the nature of any specific cell/cell or cell/matrix interaction that might be affected by the disintegrin domain within SEQ ID NO:12. The assertion that a claimed product may be used as a molecular mass marker does not rise to the level of a specific utility - other polypeptides will serve this purpose - and no disclosure in the specification indicates that at the time the application was filed Applicant was aware of any specific utility for a SVPH-1a metalloprotease or its included disintegrin domain, that would permit its immediate use by the public. A method of using a material for further research to determine, e.g., its

Art Unit: 1652

able to describe that invention with particularity" to satisfy the description requirement of the first paragraph of 35 U.S.C. § 112. *Fiers v. Revel v. Sugano*, 25 USPQ2d 1601, 1605 (Fed. Cir. 1993). The specification furnishes no relevant identifying characteristics of polypeptides that differ from the amino acid sequence of SEQ ID NO:12 yet have "disintegrin activity", thus the specification's treatment of the claimed subject matter is considered to be entirely prospective where skilled artisans in the relevant field of molecular biology could not predict the structure of the claimed molecules.

Claims 1, 3-10, 14-22, and 26-31 are rejected under 35 U.S.C. § 112, first paragraph, because the specification, while being enabling for the preparation of a polypeptide having the amino acid sequence of the elected SEQ ID NO:12 having a disintegrin activity, does not reasonably enable preparation of amino acid sequences having disintegrin activity that diverge from the amino acid sequence of SEQ ID NO:12 by unlimited amino acid substitutions, deletions and insertions, or combinations thereof anywhere within SEQ ID NO:12. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Claims 1, 3-10, 14-22 and 26-31 are rejected for lack of enablement because they embrace unlimited, arbitrary, amino acid substitutions, additions or deletions anywhere, in any combination or pattern, within SEQ ID NO:12 but the specification cannot support such insertions, deletions, or substitutions anywhere the SVPH-1a amino acid sequence SEQ ID NO:12 yet assure a product that retains an undisclosed disintegrin activity where neither the specification nor the prior art made of record, taken together, teach where any amino acid positions might be altered, nor the nature of the alterations that may be made, which permit a resulting variant amino acid sequence to have "disintegrin activity". The specification teaches no specific disintegrin activity for the native SVPH-1a disintegrin domain of SEQ ID NO:12 with which the artisan, seeking to make even a few alterations, might assay to determine whether or not an alteration of SEQ ID NO:12 results in the loss or the retention of disintegrin activity and mere sequence perturbation will not enable the design and preparation of divergent disintegrin domains that might provide the public domain that retains its undisclosed, native, function.

specific biological role, thus identifying or confirming a "real world" context for its use, cannot be considered to be a "substantial utility". *Brenner v. Manson*, 383 U.S. 519, 148 USPQ 689 (Sup. Ct. 1966).

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-11, 14-23, and 26-31 are also rejected under 35 U.S.C. § 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

Claims 1, 3-10, 14-22 and 26-31 are rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor, at the time the application was filed, had possession of the claimed invention.

The specification fails to exemplify or describe the preparation of a polypeptide that comprises the divergent amino acid sequences of claims 1, 3-10, 14-22, and 26-31 that may differ from the amino acid sequence set forth in SEQ ID NO:12 beyond the region identified in claim 1, where the limitation "having disintegrin activity" is unsupported by the specification where the nature of the activity is undisclosed and is not demonstrated to reside entirely in the amino acid sequence region identified in claim 1. In particular, claim 27 reaches generic peptides or polypeptides that differ at as many as 10 amino acid positions within the 103-amino acid sequence of the region identified in claim 1 as well throughout the rest of the molecule. Neither the claims nor the specification can describe where amino acid differences may occur within SEQ ID NO:12 that confer the undisclosed activity nor what the differences might be. "While one does not need to have carried out one's invention before filing a patent application, one does need to be

It is well settled that 35 U.S.C. §112, first paragraph, requires that a disclosure be sufficiently enabling to allow one of skill in the art to practice the invention as claimed without undue experimentation and that unpredictability in an attempt to practice a claimed invention is a significant factor supporting a rejection under 35 U.S.C. §112, first paragraph, for non-enablement. See, *In re Wands*, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988). Applying the analysis of enablement discussed in *Wands* to Applicant's disclosure, it is apparent that:

- a) the specification lacks adequate, specific, guidance for altering the SVPH-1a amino acid sequence of SEQ ID NO:12 to the extent permitted by the claims,
- b) the specification lacks working examples wherein the SVPH-1a amino acid sequence of SEQ ID NO:12 is altered to the extent recited in the claims,
- c) in view of the prior art publications of record herein, the state of the art and level of skill in the art do not support such alteration, and,
- d) unpredictability exists in the art where no members of the class of proteases represented by the amino acid sequence of SEQ ID NO:12 had even a few amino acid positions identified for concurrent modification.

Thus the scope of subject matters embraced by amino acid sequence alterations beyond the region identified in claim 1, and particularly amino acid sequence alterations embraced by claim 27 within the region identified in claim 1, is unsupported by the present specification, even if combined with the teachings available in the prior art.

The following is a quotation of the second paragraph of 35 U.S.C. § 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-11, 14-23, and 26-31 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1, 6, 15 and 27 are indefinite in stating, "having disintegrin activity", where the nature of the recited activity is not disclosed in the specification, thus the artisan and the public seeking to determine the metes and bounds of the intended subject matter cannot know what is covered by the claims. Claims 2-5, 7-11, 14, 16-23, 26, and 28-31 are included in this rejection because they depend from claims 1, 6, 15 and 27 but do not otherwise resolve the ambiguity of the claims from which they depend.


Conclusion

While rejected above under 35 U.S.C. §§ 101 and 112, claims 1-11, 14-23, and 26-31 describing either the integral SVPH-1a metalloprotease of SEQ ID NO:12 or a polypeptide that comprises the included disintegrin domain comprising amino acids 389 through 491 of SEQ ID NO:12 are free of the prior art of record herein, including the prior art made of record with Applicant's Information Disclosure Statement filed 19 September 2003. The ADAM 20 metalloprotease-disintegrin disclosed in 1998 by Hooft van Huijsduinen has an amino acid sequence that shares an overall 48.7% identity with that of SEQ ID NO:12 herein and shares 72.5% identity in the region corresponding to the disintegrin domain described by claim 1. There is no disclosure before Applicant's January 1999 priority date of a disintegrin domain amino acid sequence having a closer sequence relationship to the disintegrin domain of SEQ ID NO:12 herein than that of ADAM 20 metalloprotease-disintegrin.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to William W. Moore whose telephone number is now 571.272.0933. The examiner can normally be reached between 9:00AM and 5:30PM EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Ponnathapura Achutamurthy, can be reached at 571.272.0928. The fax phone number for all communications for the organization where this application or proceeding is assigned is 571.273.8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571.272.1600.

William W. Moore
25 June 2005



NASHAAT T. NASHED PHD.
PRIMARY EXAMINER

Notice of References Cited		Application/Control No.	Applicant(s)/Patent Under Reexamination	
		10/664,456	CERRETTI, DOUGLAS P.	
Examiner William W. Moore		Art Unit 1652	Page 1 of 1	

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-5,883,241	03-1999	Docherty et al.	536/23.2
*	B	US-6,485,956	11-2002	Cerretti, Douglas P.	435/219
*	C	US-6,673,549	01-2004	Furness et al.	435/6
*	D	US-6,683,165	01-2004	Keith et al.	536/22.1
*	E	US-2002/0042368	04-2002	Fanslow et al.	514/12
*	F	US-2003/0118997	06-2003	Bejanin et al.	435/6
*	G	US-2003/0194797	10-2003	Young et al.	435/226
*	H	US-2004/0119171	06-2004	Chen et al.	257/778
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
*	N	WO 2001/62905	08-2001	WIPO	Fanslow et al.	----
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2517-USB	SERIAL NO. 10/XXX,XXX (continuation of 09/890,323)		
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				APPLICANT Douglas P. Cerretti			
				Filing Date: September 19, 2003	GROUP <i>TBD 1652</i>		
U.S. PATENT DOCUMENTS							
EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
<i>ADM</i>	B1	WO99/36549	07/22/99	WIPO	—	—	
OTHER DOCUMENTS (<i>Including Author, Title, Date, Pertinent Pages, Etc.</i>)							
<i>ADM</i>	C1	Cerretti DP et al, "Isolation of Two Novel Metalloproteinase-Disintegrin (ADAM) cDNAs that Show Testis-Specific Gene Expression," <i>Biochemical and Biophysical Research Communication</i> , 263: 810-815, 1999					
<i>ADM</i>	C2	Jones M et al. "Chromosomal Assignment of 3XX Sequences Transcribed in Testis," (References 1 and 2), GenBank Accession No. X85598, June 1995					
<i>ADM</i>	C3	Hooft van Huijsduijnen R, "ADAM 20 and 21; Two Novel Human Testis-Specific Membrane Metalloproteases with Similarity to Fertilin- α ," <i>Gene</i> 206:273-282, 1998					
<i>ADM</i>	C4	Xu R et al. "Molecular Cloning and Mapping of a Novel ADAM Gene (ADAM29) to Human Chromosome 4," <i>Genomics</i> , 62: 537-539, 1999					
EXAMINER <i>William Moore</i> <i>28 June 2005</i>							

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NEW CENTRAL FAX NUMBER

Effective July 15, 2005

On July 15, 2005, the Central FAX Number will change to **571-273-8300**. This new Central FAX Number is the result of relocating the Central FAX server to the Office's Alexandria, Virginia campus.

Most facsimile-transmitted patent application related correspondence is required to be sent to the Central FAX Number. To give customers time to adjust to the new Central FAX Number, faxes sent to the old number (703-872-9306) will be routed to the new number until September 15, 2005.

After September 15, 2005, the old number will no longer be in service and **571-273-8300** will be the only facsimile number recognized for "centralized delivery".

CENTRALIZED DELIVERY POLICY: For patent related correspondence, hand carry deliveries must be made to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), and facsimile transmissions must be sent to the Central FAX number, unless an exception applies. For example, if the examiner has rejected claims in a regular U.S. patent application, and the reply to the examiner's Office action is desired to be transmitted by facsimile rather than mailed, the reply must be sent to the Central FAX Number.